BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Restellini S, Afif W. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. J Clin Med 2021;10:1242. [PMID: 33802816 DOI: 10.3390/jcm10061242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hirayama H, Morita Y, Imai T, Takahashi K, Yoshida A, Bamba S, Inatomi O, Andoh A. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease. BMC Gastroenterol 2022;22:195. [PMID: 35448957 DOI: 10.1186/s12876-022-02271-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang MY, Zhao JW, Zheng CQ, Sang LX. Therapeutic drug monitoring in inflammatory bowel disease treatments. World J Gastroenterol 2022; 28(15): 1604-1607 [DOI: 10.3748/wjg.v28.i15.1604] [Reference Citation Analysis]
3 Truta B. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place. World J Gastroenterol 2022; 28(13): 1380-1383 [DOI: 10.3748/wjg.v28.i13.1380] [Reference Citation Analysis]
4 Noor NM, Sousa P, Paul S, Roblin X. Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD. Inflamm Bowel Dis 2021:izab228. [PMID: 34480558 DOI: 10.1093/ibd/izab228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]